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ABSTRACT: The present study analyzed the effect of intra-ao 
cumbens administration of the stereoisomers of sulpiride upon 
(3l4-dihydroxyphenylim ino)-2-im ida2ollne (DPI)-induced 
changes In oral behaviours and electromyographic patterns of 
Jaw muscles. In line with earlierfindings, DPI (5 fxg) administered 
Into the nucleus accumbens increased chewing and tremor, /- 
Sulpiride (2~S0 ng) had no effect on DPI-induced oro-facial be­
haviours, d-Sulpiride (10-50 ng) significantly antagonized the 
DPMnduced increase in chewing and had a bfphasic effect on 
tremor with potentiation (10 ng) followed by attenuation (50 ng). 
When administered alone, /- or d-sulplride did not affect oro« 
facial behaviours. The electromyographic signals, which were 
analyzed according to a previously described method, were de­
scribed with the help of three classes: A (the seconds marked 
by frequency 3 Hz), 8 (the seconds marked by the frequencies 
4-6 Hz); C (the seconds marfced by the frequencies 7-15 Hz). 
DPI enhanced Class B and C of the masseter muscle but did not 
significantly affect any frequency class of the digastric muscle. 
/-Sulpiride (2-50 ng) had no effect on DPI-induced (5 /xg) 
changes In electromyographic signals. d-Sulpiride (50 ng) an­
tagonized the effects of DPI on Class B of the masseter muscle. 
Furthermore, d-sulplride had a biphasic effect on Class C with 
potentiation (10 ng) followed by attenuation (50 ng), When ad­
ministered alone, or d-sulplride did not affect the frequency 
classes of the jaw muscles. It is concluded that cf-sulplride in­
hibits DPMnduced changes In oral behaviour and electromyo­
graphic patterns, it is suggested that d-sulpiride may be effec­
tive in the pharmacotherapy of oro-facial dyskinesias in man.
KEY WORDS: Oro-facial dyskinesia, Electromyography, Jaw 
muscle, DPI, Stereoisomers, Neuroleptic,
INTRODUCTION
The nucleus aecumk*ns modulates oro-facial hehaviour in rats 
|.V5,K,l7Jl) 221 More specifically, intra-aeeumbens adminis­
tration ut t ,M dihydm \yphenylim inol"2 -imida¿oline (DPI), 
which is considerai to be a dopamine DA, receptor agonist [6,7], 
increases several orofacial hehaviours in rats |22 |. This effect is 
subregion specific, because DPI affects oral behaviour when ad­
ministered into the shell, but not the core or the rostral pole of 
the nucleus accumbens; moreover, DPI-injections into sues ad­
jacent to this nucleus remain ineffective (8 ,2 2 , unpublished ob­
servations). The shell, being the region in which DPI induces
oral behaviours, is especially important, because the dopami­
nergic activity in the shell, but not the core, of the nucleus ac­
cumbens in rats is sensitive to stressors [10], Sensitivity to stres­
sors is also a characteristic of oro-facial dyskinesias in man [16]. 
Moreover, intra-accumbens administration of high doses o f DPI 
induces dyskinetic-like oral behaviour (large amplitude chewing 
[2 2 ]), this in contrast with administration of dopamine D| and D 2 
agonists [17]. Therefore, DPI-induced oro-facial behaviour in 
rats has been suggested to be an interesting animal model o f  oro­
facial dyskinesias in man [2 2 ],
Because the pharmacotherapeutic treatment of oro-facial dys­
kinesias in man is a major problem [14,15], it became of interest 
to find drugs that attenuate the DPI-induced oral behaviours. A  
possible candidate for such a drug is sulpiride. It has been found 
that sulpiride shares its high affinity for the so-called mesolimbic 
/-sulpiride binding site (7 nM) in the nucleus accumbens with 
that of DPI [2 -5  nM] [9; Csernansky, personal communication]. 
Interestingly, in contrast to its affinity for dopamine D 2 receptors, 
the affinity of sulpiride to the /-sulpiride binding site is not ste- 
reospecific [/-sulpiride: 7 nM; ¿/-sulpiride: 9 nM] [9]. Therefore, 
the effects of intra-accumbens administration of different doses 
of /- and ¿'/-sulpiride on spontaneous and DPI-induccd oro-facial 
behaviour were analyzed in the present study. Given the possi­
bility that the sulpiride stereoisomers might increase or decrease 
the effects of DPI, a relatively low dose of DPI was chosen [5 
¡igj [22j. Because the effects of DPI-injections into the border 
region of the core and shell (the so-called “ shore”  [22 ]), which 
is easy to hit correctly, are largely comparable to DPI-injections 
into the shell, which is difficult to hit [22 ], it was decided to use 
“ shore1’ injections in the present study. Finally, together with 
the behavioural assessment, electromyographical (EMG) mea­
surements of jaw muscles were made. The analysis o f  the signals 
according to a previously described method [21] provided an­
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lines. Naive, male Wistar rats (Central Animal Laboratory, Nij­
megen) were used. Before operation they weighed between 180 
and 220 g. Rats were individually housed and kept on a 12-h 
day/night cycle with lights on at 7:00 am. Food and water were 
available ad lib. Animals were used only once.
Surgery
Animals were anaesthetized with sodium pentobarbital (Nar- 
covet, 60 mg/kg IP). Guide cannulas (0.65 mm outer diameter, 
0.3 mm inner diameter) were stereotactically implanted into the 
nucleus accumbens, viz. the border region of the core and shell 
(ant. 9.8 mm; vert. 2.7 mm; lat, 1.2 mm). Cannulas (5 mm length) 
were angled 10 degrees from the midsagittal plane to avoid the 
ventricular system and to leave space for an electromyographic 
(EMG) connector. The cannulae and a five-pinned plug con­
nected with five biomed wires (Cooner Wire, AS 632-4SS) were 
attached to the skull with dental acrylic cement (Durelon, ESPE). 
Four of the five biomed electrodes were subcutaneously led to 
the jaw muscles (for details see [21]). Two electrodes were uni­
laterally placed in the right anterior superficial part of the mas­
seter muscle; two other electrodes were unilaterally placed in the 
right anterior part of the digastric muscle. The fifth wire was 
placed subcutaneously in the neck and served as a grounding 
electrode.
Apparatus
During the experiments rats were placed in a cage of Plexiglas 
(25 cm X 25 cm X 35 cm). A mirror (angled 45 degrees) was 
mounted beneath the cage allowing the precise recording of be­
haviour, especially of oro-facial movements. Behaviour was reg­
istered using a protocol panel with 16 channels. The behavioural 
protocols and the EMG signals (transmitted by electric wires cou­
pled to a swivel) were directly read into a computer and analyzed 
by a computer program that calculated the frequency and dura­
tion o f every scored behaviour. The analysis o f the EMG signals 
is described below.
Procedure
The procedure is described elsewhere in detail [22]. After sur­
gery the rats were housed individually in the original stockroom 
and allowed recovery from operation for at least 1 week. After 
the recovery period, the rats were handled on three subsequent 
days and tested on the fourth day (between 9.00  and 17.00 h). 
The handling and test procedures were preceded by a habituation 
time of 45 min, On the third day, a sham injection was given, 
the rats were connected with the EMG device and placed in the 
experimental box for 10 min. On the test day, intracerebral in­
jections with distilled water were bilaterally given at t =  - 3  min. 
Registration of baseline activity started at t =  0 min and lasted 
30 min (pretreatment session). The animals were given a second 
injection with /-sulpiride, d-sulpiride or distilled water at / = 55 
min. Finally, the animals received their last intracerebral injection 
of DPI or its control (distilled water) at t = 57 min. Registration 
of the drug effects started at t =  60 min and lasted 30 min (ex­
perimental session). The injections were given by means of a 5 
/il Hamilton syringe with a 0.25 mm needle that extended 2 mm 
into the brain tissue below the tip of the permanent embedded 
cannula. The volume was 0.5 p\ per side injected over a 10 s 
period, and the needle was left in situ for another 10 s to minimize 
diffusion along the needle tract.
After the experiment the rats were sacrificed, and the brains 
were dissected. Brain sections were stained with cresyl violet and
microscopically analyzed. Only data from subjects with injec­
tions made into the desired sites (about 90% o f  total) were further 
analyzed. All groups consisted of six to nine animals after ex­
cluding rats with misplaced injections (N = 11),
Behavioural Observations
The ethogram of behavioural elements was similar to that de­
scribed earlier [2 2 ]: ( 1) chew (movement of the lower jaw ver­
tical and/or lateral in a single or repetitive fashion without an 
object between the teeth); (2 ) abnormal chewing, being large am­
plitude chewing (wide opening and closing o f  the lower jaw in 
a brisk repetitive fashion); (3) gnaw (movement o f the lower jaw 
vertical and/or lateral in a single or repetitive fashion with an 
object (pieces o f straw, faeces, or the box wall) between the 
teeth); (4 ) tremor (rapid oscillations o f cheek and/or lower jaw); 
(5 ) tongue protrusion (not aimed at an object); (6 ) lick (tongue 
protrusion aimed at an object); (7) yawn (wide opening o f the 
lower jaw with bare teeth), Continuous succession of identical 
elements of behaviour (bouts) were scored as a single event. Du­
ration (except for tongue protrusion and yawn) and frequency of 
all behaviours were analyzed.
Analysis o f  EMG Signals
The analysis o f the EMG signals was based upon an earlier 
described method [21], However, some significant modifications 
were made, for example, signals were directly read in the com­
puter and were on-line analyzed. Furthermore, the settings for 
minimum values concerning the assignment o f a frequency to a 
second (see below) were slightly modified. This modified method 
will be shortly summarized. First, EMG signals were high-pass 
filtered (80 Hz) before they entered the computer. The signals of 
the masseter and the digastric muscle were analyzed indepen­
dently, but in the same manner. The signals were divided in parts 
of 1 s, rectified and smoothed. Subsequently, the data were sub­
jected to a fast-fouricr transformation (FIT) per block of I s. 
This analysis offered two parameters: (a) the power per second 
being the area under the curve of the EMC! signal per second; 
and (b) the frequency distribution curve per second. The power 
was used as a criterion for the assignment o f  a frequency to a 
second (see below). The dominant frequency per second was 
determined in the following manner. The proportional contribu­
tion of the area belonging to a frequency (e.g., the area from 5.5 
to 6.5 for frequency 6 ) under the frequency distribution curve as 
compared to the total area under the frequency distribution curve 
(from 3 to 20 Hz) was calculated per second. The proportionally 
greatest area under the curve was labelled as the dominant fre­
quency. To assign the dominant frequency to a second, two con­
ditions had to be fulfilled. First, the dominant frequency had to 
be a salient feature of the second under studv. For that reason,
w
the proportional contribution o f the dominant frequency per sec­
ond had to surmount a minimum percentage (25%, present study 
vs, 14% in our previous study (21 )| o f  the total area under the 
frequency distribution curve (3 to 20 Hz) of that second. Second, 
the EMG activity per se had to be a salient feature o f the second 
under study. For that reason, the power \k i  ,sccond had to sur­
mount a minimum, which was 500 and 50 for the masseter and 
digastric muscle, respectively. Only when both restrictions were 
fulfilled was the dominant frequency accepted as a marker o f the 
second under study; otherwise the second was not taken into 
account. The total number o f seconds marked by a distinct dom­
inant frequency was the dependent variable.
One more restriction was made before the final HMG results 
were further analyzed. A prelimary, unpublished study in which
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FIG. L The eifects of intra-accumbens administration of H;0 , DPI, and co- 
adminisiratkm of I- tir </~sulpiride with DPI on the frequency and duration (s) 
of two different oro-facial behaviours. Means and SEMs are shown of baseline 
controlled values: the 30 min pretreatment baseline values were subtracted from 
the 30 ruin posttreatment values. N ~ 6—9/group. *p < .05 (for statistics, see 
text).
the display of behaviour was directly correlated with the presence 
of the dominant frequency per second had shown that the display 
of both chewing and grooming correlates with the presence of 
the frequencies 4 6 ; moreover, it had been found that the display 
of tremor correlates with the presence of the frequencies 7 —15. 
To prevent that the presence of long-lasting grooming bouts 
would mask the detection of chewing in the KMG-analysis, EMG 
data that were collected during the display of grooming were 
therefore discarded in the present HMG analysis.
Drugs
( 3,4 4  ) i hy drox y plie ny I i m i no ) -2- i m i d azo i i ne ( D PI, B oc h ri ngc r 
Ingelheim, FRO) was dissolved in water. The stereoisomers of 
sulpiride (RBI, Natick, USA) were dissolved in distilled water 
and a drop of acetic acid after which the pH was adjusted to 6 -  
7, Drugs were injected bilaterally.
Statisi it* til Arta I vs is
)
Like in our previous study |22|, the scores collected per rat 
during the pretreatment session were subtracted from the scores 
collected i>er rat during the experimental session to control for 
the individual variation in oro-facial behaviours. Only the re­
sulting data were statistically analyzed. The effects of DPI on 
different behaviors or on the number o f seconds characterized by 
a frequency were analyzed with a one-way analysis of variance 
(ANOVA) vvith two levels (water and DPI). The effects of dif­
ferent doses of /- or «/-sulpiride upon the DPI-induced effects 
were analyzed with one-way analysis o f variance (ANOVA) with 
four levels (DPI and 2, 10, and 50 ng of /-sulpiride; DPI and 10, 
25, and 50 ng of ¿/-sulpiride), followed by the post hoc Student- 
Newman Keuls test when appropriate. Possible significant ef­
fects of /-sulpiride or (/»sulpiride alone (10 and 50 ng) were de­
termined with one-way A NOV As.
RESULTS
Behavioural Analysis: Effects o f DPI
Because the scores in the pretreatment session were subtracted 
from those in the experimental session (see Materials and Meth­
ods section), the resulting scores could be either negative or pos­
itive (Figs. 1 and 2; cf, [22]). In line with earlier studies, DPI (5 
pg) increased oro-facial behaviours: the frequency of chewing 
[F(l, 17) = 10.4; p <  0.01; Fig. 1], large amplitude chewing 
IF(L 17) = 5.7;/? = 0.03J, gnawing [F(l, 17) -  8.65;/? <  0.01], 
tremor {[F( 1, 17) = 4.3; p  =  0.05]; Fig. 1}, and tongue protru­
sions [F( 1, 17) -  6.73; p =  0 .02], but not of licking [F{ 1, 17) =  
1.85; p =  0.I9J and yawning [F(l, 17) = 1.31; p =  0.27], was 
significantly increased. DPI also significantly increased the du­
ration of chewing [F(l, 17) =  11.76; p <  0 .01; Fig. 1], large 
amplitude chewing [^(1, 17) = 5.19; p -  0,04], and gnawing 
[F( 1, 17) = 10.53; p  <  0.01], but not of tremor {[^(1, 17) =  
2.76; p =  0.11.1; Fig. 1} and licking [F(l, 17) -  0,21; p «  0.65].
Behavioural Analysis: Effects o f Sulpiride Stereoisomers on
DPI
/-Sulpiride did not affect any oral behaviour induced by DPI. 
¿/-Sulpiride significantly affected the frequency [F(3, 20) =  5.02; 
p  <  0.01 ] and duration of chewing [(F(3, 20) =  5.87; p <  0,01], 
With respect to both chewing frequency and duration, there was 
an apparent dose-dependeni decrease (Fig. 1), ¿/-Sulpiride sig­
nificantly affected the frequency [F(3,20) -  6.02;p  <  0.01] and 
the duration of tremor [F('J, 30) = 7.56; p <0 .01; Fig. 1]. Tremor 
duration was enhanced by the lowest dose of ¿/-sulpiride and 
attenuated by the highest dose of ¿/-sulpiride. Tremor frequency 
showed similar, but nonsignificant, effects (Fig. 1). None of the 
other DPi-induced behaviours (i.e., large amplitude chewing, 
gnawing, and tongue protrusions) were significantly affected by 
¿/-sulpiride according to the ANOVA. However, inspection of the 
data suggested that this was due to the fact that DPI had small
104
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FIG, 2. The effects of in tra-accumbens administration of H.*0, /-sulpiride, and d-sulpiride on the frequency 
and duration (s) of chewing and tremor. Means and SEMs are shown of baseline controlled values: the 30 
min pretreatment baseline values were subtracted from the 30 min posttreatment values. N ~ (v ()/£roup.
effects (cf. [22]) rather than to a lack of effect of ¿/-sulpiride, 
which ncmsignificantly attenuated all these oral behaviors (data 
not shown).
feront behaviours, /- und ¿/-sulpiride showed the same lack of 
e f fee t as f o r fre queney.
Behavioural Analysis: EJfects o f Sulpiride Stereoisomers Alone
The effects of the sulpiride stereoisomers alone were studied 
in a similar way as were the effects of the stereoisomers on DPI 
(using baseline-controlled values, see Materials and Methods 
section). However, the experimental session values of the H20 /  
H20  control group for (he frequency of gnawing (mean ±  SEM:
0.1 ±  0.1), tongue protrusions (5.1 ±  2.0), yawning (0.8 ±  0.5) 
and large amplitude chewing (0.1 ±  0 . 1) were very low, and 
therefore a possible attenuating effect of the sulpiride stereoiso­
mers could not be determined. Although a possible decrease in 
these behaviours could not be determined, neither /-sulpiride nor 
¿/-sulpiride induced an increase in any of these behaviours (data 
not shown). The experimental session value of the H20 /H 20  con­
trol group for the tremor frequency was also reasonably low 
(mean ±  SEM: 11.8 ±  3.5). Therefore, apart from analyzing the 
tremor frequency in the normal way (using baseline-controlled 
values, see above), it was also analyzed by comparing the ex­
perimental session values of the sulpiride stereoisomer groups 
with those of the H2O/H2O control group (data not shown). /- 
Sulpiride and ¿/-sulpiride did not influence tremor: neither the 
baseline-controlled values nor the experimental session values 
(Fig. 2) were significantly different from those of the controls. 
The experimental session value of the H20 /H 20  control group 
for the chewing frequency was very high (means ±  SEM: 77.0 
±  6-0 ); therefore, this parameter could be analyzed in a normal 
way. None of the doses tested of /-sulpiride or ¿/-sulpiride af­
fected chewing (Fig. 2), With respect to the duration of the dif-
Electromyog raph ¡cal A nal y  sis: Effet 'ts o f DPI
As for the behavioral items, the EMG data were baseline- 
controlled, and the resulting scores could be either negative or 
positive (Fig. 3). In line with an earlier study |22 |, the drug- 
induced effects on distinct frequencies could easily be described 
with the help of three main classes of frequencies, Class A (fre­
quency 3 Hz), Class 13 (frequency 4- 6 Hzh and Class C (fre­
quency 7 -1 5  Hz), DPI had no effect on Class A. On the other 
hand, DPI significantly enhanced Class B [/♦'( K 17) ~ 8 .2e); p ~
0.01] and Class C [H I, 17) -  4.84; p -  0 .041 of the masseter 
muscle. DPI did not affect any frequency class of the digastric 
muscle.
Elcctromyot>raphical A nalysis: Effects o f Sulpiride 
Stereoisomers on DPI
/-Sulpiride did not significantly affect the DPI-induced EMG 
effects (Fig. 3). ¿/-Sulpiride significantly affected Classes R [H3, 
28) = 3.84; p < 0.05] and C [FiX 28) -  I0 .c>; /> <  0 .0 1 1, but 
not Class A, of the masseter muscle. Class B was siginficantly 
attenuated by 50 ng ¿/-sulpiride (Fig. 3), whereas Class C was 
enhanced by a low dose (10 ng; p  <  0.05) and attenuated by a 
high dose (50 ng; p <  0.05; Fig. 3). Although the EMG results 
of the digastric muscle were not significantly affected by DPI, <7- 
sulpiride showed an overall effect on Class C ¡ƒ*’(3, 28) -  5.c)5; 
p  <  0.01 ]. Again, an enhancement f 10 ng) of DPI was followed 
by a decrease (50 ng; data not shown).
Frequencies 4 to 6 Hz.
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Eleciromxoxraphical Analysis: Effects o f Sulpiride 
Stereoisomers Ah me
As for the behavioral analysis* both the baseline-controlled 
values and the ex(H?ri mental values of the Classes A> C were 
analyzed. No significant effect was found for one of the classes 
(if either the masseter or the digastric muscle.
DISCUSSION
The eifects of in tra-accumbens administration of /- and tl- 
sulpiride on (,M"dihydroxyphenylimino)-2-imidazoline (DPI)- 
induced oral behaviours were studied in freely moving rats, DPI 
is known to affect oral behaviour when injected into the shell, 
but not into more rostral, ventral, dorsal, or caudal regions (sec 
Introduction section). Moreover, sulpiride is known to be very 
hydrophilic and to diffuse little after intracerebral administration 
[2JK|. This, together with the fact that the injections were placed 
in the central nucleus accumbens (the border region of the core 
and shell, see Introduction section), allows the conclusion that 
all the observed drug-induced effects were due to pharmacolog­
ical actions within the nucleus accumbcns.
In line with an earlier study [22|, DPI significantly increased 
the oral behaviours chewing and tremor, These effects were not 
affected hy /-sulpiride. On the other hand, ¿/-sulpiride signifi­
cantly attenuated the effects of DPI on chewing and tremor. This 
was not due to a nonspecific effect o f ¿/-sulpiride* because it did 
not inhibit these behaviours when administered alone. Although 
the obser\er was not blind to the treatment, the validity ol the 
acquired data is strongly supported by the results of the electro­
myographic (HMCÎ) analysis. First, the HMG effects of DPI on
the masseter muscle were antagonized by d-sulpiride, but not /- 
sulpiride. Second, d-sulpiride given alone showed no EMG ef­
fect. And, finally, the behavioural changes in chewing co-oc­
curred with the frequencies 4 - 6  Hz, whereas those in tremor 
co-occurred with the frequencies 7 -1 5  Hz; these observations 
fully lit in with the finding in our previously unpublished study 
showing that the display of chewing and that of tremor nicely 
correlate with the occurrence of the frequencies 4 - 6  Hz and that 
of the frequencies 7 -1 5  Hz, respectively (see Materials and 
Methods). Taken together, these EMG data strongly support the 
behavioural results.
Comparing both methods, it is clear that both the behavioural 
analysis and the EMG analysis are able to detect drug-induced 
changes in oral behavior. However, it is important to note that 
EMG analysis alone is insufficient for detecting which oral be­
haviour is affected: apart from the noted correlations (tremor and 
frequencies 7 -1 5  Hz; chewing and frequencies 4 - 6  Hz), no 
other correlations were found. Nevertheless, the value of this 
method is evident: it is an objective method that can be used to 
(in)validate the assessment of the behavioural method.
The finding that ¿/-sulpiride attenuates the effects of DPI on 
oro-facial behaviours suggests that dopamine receptors were 
not involved, because d-sulpiride has a relatively small affinity 
for these receptors [1,13,26,27,29,30]. Moreover, actions on do­
pamine D2 or D.* receptors causing the attenuation of DPI-in­
duced oral behaviours can be excluded because/-sulpiride, which 
is a stronger antagonist of both receptors than d-sulpiride (see 
below), is without effect on DPI-induced oral behaviours. This 
is underscored by the finding that a low dose of /-sulpiride (2 ng) 
with a dopamine Dn and D* receptor blockade comparable to the 
effective dose of ¿/-sulpiride (50 ng; [1,11,26,27] did not affect
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DPI-induced behaviours. The stereoselective action oí ¿/-sulpir­
ide also suggests that the so-called mesolimbic /-sulpiride bind­
ing site is not involved, because ¿/-sulpiride and /-sulpiride have 
identical affinities for this site [9], Still, it cannot be excluded 
that the ineffectiveness of /-sulpiride was due to its potency to 
interact with both the mesolimbic /-sulpiride binding site and 
dopamine D2 or D.^  receptors; for, combined binding may limit 
the relative occupancy and, thus, the degree of antagonism of /- 
sulpiride at each of the binding sites separately. Further research 
is required to characterize the actual target site of ¿/-sulpiride.
Irrespective of the precise mechanism involved, ¿/-sulpiride 
strongly attenuated DPI-induced oral behaviour. The present data 
imply that ¿/-sulpiride may ameliorate oro-facial dyskinesias in 
man (see Introduction). Because d-sulpiride has a very low affin­
ity for dopamine Di receptors, it may have therapeutic effects on 
oro-facial dyskinesia in schizophrenic patients as well as in Par­
kinson’s patients without aggravating the extrapyramidal side- 
effects of neuroleptics or without attenuating the therapeutic ef­
fects of l-DOPA, respectively. As far as we know, no clinical 
studies with ¿/-sulpiride have been performed. However, the ra- 
cemic mixture of sulpiride has been studied in schizophrenic pa­
tients: it ameliorates oro-facial dyskinesias when given alone 
[4,12,23] and when given in combination with other neuroleptics 
[4,25]. These findings seem to support the clinical implication 
postulated above, although it cannot be excluded that the anti- 
dyskinetic effect of ¿//-sulpiride seen in the clinic was (partly) 
due to D2 receptor blockade caused by /-sulpiride. For, antag­
onists like classical neuroleptics are known to ameliorate oro­
facial dyskinesia [14,15]. Nevertheless, the present findings sug­
gest that ¿/-sulpiride may have anti-dyskinetic effects. If so* 
¿/-sulpiride is of interest as an adjuvans to l-DOPA in the phar­
macotherapy of Parkinson’s patients, counteracting the devel­
opment of oro-facial dyskinesias. However, it should bc realized 
that the specificity of ¿-sulpiride will be limited to lower doses, 
because higher doses can affect dopamine D2 receptors as well. 
Furthermore, ¿//-sulpiride may be of interest in the pharmaco- 
therapeutic treatment of schizophrenia, having therapeutic effects 
(/-sulpiride) while counteracting the development of oro-facial 
dyskinesias (¿/-sulpiride). Indeed, ¿//-sulpiride chronically admin­
istered induces less oro-facial dyskinesias than classical neuro­
leptics ([24] and references therein).
In sum, ¿-/-sulpiride (10-50  ng) administered into the nucleus 
accumbens inhibited DPI-induced oral behaviours and jaw mus­
cle EMG changes, in a specific manner, for: ¿/-sulpiride did not 
inhibit these effects when given alone. The much more potent 
antagonist of dopamine D2 receptors /-sulpiride (2 -5 0  ng) was 
ineffective on DPI-induced effects.
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